The translational revolution and use of biologics in patients with inflammatory skin diseases

Shinji Noda; James G. Krueger; Emma Guttman-Yassky

doi:10.1016/j.jaci.2014.11.015

The translational revolution and use of biologics in patients with inflammatory skin diseases

Shinji Noda, James G. Krueger, Emma Guttman-Yassky

Research output: Contribution to journal › Article › peer-review

170 Scopus citations

Abstract

Psoriasis and atopic dermatitis (AD) are common inflammatory skin diseases characterized by immune-mediated inflammation and abnormal keratinocyte differentiation. Although T-cell infiltration characterizes both diseases, T-cell polarization differs. Psoriasis is currently the best model for translational medicine because many targeted therapeutics have been developed and testing of targeted therapeutics has cemented psoriasis as IL-23/T_H17 polarized. In patients with AD, although therapeutic development is approximately a decade behind that in patients with psoriasis, there is now active development and testing of targeted therapeutics against various immune axes (T_H2, T_H22, and IL-23/T_H17). These clinical trials and subsequent molecular analyses using human samples will be able to clarify the relative roles of polar cytokines in patients with AD.

Original language	English
Pages (from-to)	324-336
Number of pages	13
Journal	Journal of Allergy and Clinical Immunology
Volume	135
Issue number	2
DOIs	https://doi.org/10.1016/j.jaci.2014.11.015
State	Published - 1 Feb 2015

Keywords

IL-23
Psoriasis
T17
T2
T22
atopic dermatitis
biologics
eczema

Access to Document

10.1016/j.jaci.2014.11.015

Cite this

@article{a100570437984d1a8a599c11bfb05038,

title = "The translational revolution and use of biologics in patients with inflammatory skin diseases",

abstract = "Psoriasis and atopic dermatitis (AD) are common inflammatory skin diseases characterized by immune-mediated inflammation and abnormal keratinocyte differentiation. Although T-cell infiltration characterizes both diseases, T-cell polarization differs. Psoriasis is currently the best model for translational medicine because many targeted therapeutics have been developed and testing of targeted therapeutics has cemented psoriasis as IL-23/TH17 polarized. In patients with AD, although therapeutic development is approximately a decade behind that in patients with psoriasis, there is now active development and testing of targeted therapeutics against various immune axes (TH2, TH22, and IL-23/TH17). These clinical trials and subsequent molecular analyses using human samples will be able to clarify the relative roles of polar cytokines in patients with AD.",

keywords = "IL-23, Psoriasis, T17, T2, T22, atopic dermatitis, biologics, eczema",

author = "Shinji Noda and Krueger, {James G.} and Emma Guttman-Yassky",

note = "Publisher Copyright: {\textcopyright} 2014 American Academy of Allergy, Asthma & Immunology.",

year = "2015",

month = feb,

day = "1",

doi = "10.1016/j.jaci.2014.11.015",

language = "English",

volume = "135",

pages = "324--336",

journal = "Journal of Allergy and Clinical Immunology",

issn = "0091-6749",

publisher = "Mosby Inc.",

number = "2",

}

TY - JOUR

T1 - The translational revolution and use of biologics in patients with inflammatory skin diseases

AU - Noda, Shinji

AU - Krueger, James G.

AU - Guttman-Yassky, Emma

PY - 2015/2/1

Y1 - 2015/2/1

N2 - Psoriasis and atopic dermatitis (AD) are common inflammatory skin diseases characterized by immune-mediated inflammation and abnormal keratinocyte differentiation. Although T-cell infiltration characterizes both diseases, T-cell polarization differs. Psoriasis is currently the best model for translational medicine because many targeted therapeutics have been developed and testing of targeted therapeutics has cemented psoriasis as IL-23/TH17 polarized. In patients with AD, although therapeutic development is approximately a decade behind that in patients with psoriasis, there is now active development and testing of targeted therapeutics against various immune axes (TH2, TH22, and IL-23/TH17). These clinical trials and subsequent molecular analyses using human samples will be able to clarify the relative roles of polar cytokines in patients with AD.

AB - Psoriasis and atopic dermatitis (AD) are common inflammatory skin diseases characterized by immune-mediated inflammation and abnormal keratinocyte differentiation. Although T-cell infiltration characterizes both diseases, T-cell polarization differs. Psoriasis is currently the best model for translational medicine because many targeted therapeutics have been developed and testing of targeted therapeutics has cemented psoriasis as IL-23/TH17 polarized. In patients with AD, although therapeutic development is approximately a decade behind that in patients with psoriasis, there is now active development and testing of targeted therapeutics against various immune axes (TH2, TH22, and IL-23/TH17). These clinical trials and subsequent molecular analyses using human samples will be able to clarify the relative roles of polar cytokines in patients with AD.

KW - IL-23

KW - Psoriasis

KW - T17

KW - T2

KW - T22

KW - atopic dermatitis

KW - biologics

KW - eczema

UR - http://www.scopus.com/inward/record.url?scp=84922352134&partnerID=8YFLogxK

U2 - 10.1016/j.jaci.2014.11.015

DO - 10.1016/j.jaci.2014.11.015

M3 - Article

C2 - 25541257

AN - SCOPUS:84922352134

SN - 0091-6749

VL - 135

SP - 324

EP - 336

JO - Journal of Allergy and Clinical Immunology

JF - Journal of Allergy and Clinical Immunology

IS - 2

ER -

The translational revolution and use of biologics in patients with inflammatory skin diseases

Abstract

Keywords

Access to Document

Fingerprint

Cite this